We are monitoring the impact of COVID-19 on North America Generic Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 2091
Share on
Share on

North America Generic Drugs Market Research Report - Segmented By Type, Application, & Country (the United States, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 2091
Pages: 145

North America Generic Drugs Market Size (2021 to 2026)

The size of the North America Generic drugs market has been calculated at USD 87.04 billion in 2021. It is expected to reach USD 121.45 billion by 2026, growing at a CAGR of 6.89% between 2021 to 2026.

Generic drugs have the same dosage, safety, effects, side effects, intended use, risks, and strength as a genuine drug. An example of a generic drug for diabetes is metformin. They are cost-effective compared to branded drugs. Generic drugs are also known as abbreviated drugs. To sell a generic drug, the manufacturing company must submit an Abbreviated New Drug Application for approval. This market will increase tremendously during the forecast period.

The cost-effectiveness of abbreviated drugs has given it a competitive lead over branded drugs in the market. A key driving factor for generic drugs is patent expiry for branded drugs. Patent for Branded drugs with sales of up to USD 135 billion was expired in 2015. Nearly USD 150 billion worth of patents for branded drugs will expire by 2020, which will give generic drugs a huge advantage. 

One more trend which influences market growth is outsourcing. Currently, most doctors in the US are prescribing generic drugs, which will improve even further. As a result, vendors are using outsourcing to reduce their capital which will be an advantage to generic drugs. The only restraint for this market is rigid rules set up by the FDA for approval of these drugs and the threat of counterfeit drugs.

Factors such as increased disposable incomes, the cost-effectiveness of the drugs, and the rising prevalence of chronic diseases are significant factors boosting the North American generic drugs market. In addition, the key drivers of the market are patent expiry and the adoption of thorough evaluations by various regulatory agencies to guarantee optimum standards throughout medication manufacture.

There is a lack of awareness among individuals about generic drugs, which is estimated to restrict the growth rate unleashing its full potential. They perceive them as duplicate drugs and do not seem to trust their effectiveness. Many doctors and pharmacists prescribe branded medications over generic drugs to the patients. High competition between drugs can affect the market growth during the forecast period. Also, the FDA has set up strict rules for approval of these types of drugs which makes it difficult to enter the market itself. Also, counterfeit drugs of these generic drugs are abundantly found in the market, which restricts North American generic drugs market growth.

Impact of COVID-19 on the North American generic drugs market:

Due to the global pandemic, the prices of generic medicines elevated due to the sudden increase in the demand for COVID-19 treatment, rising travel and logistics expenses.

It has impacted the demand for generic drugs as the persistence shortage in COVID-19 led to an increase in the demand. Government and manufactures strategic decisions include some collaborations, agreements with market participants. The supply of the generic drugs, as several active pharmaceutical ingredients (APIs) manufacturers in China, was unable to return due to COVID-19; some Indian generic medicine firms faced production interruption as they were the major which eventually impacted the supply chain.

This research report on the North American generic drugs market has been segmented and sub-segmented into the following categories:

By Type: 

  • Pure Generic Drugs
  • Branded Generic Drugs

By Application: 

  • The Central Nervous System (CNS)
  • Cardiovascular
  • Dermatology
  • Oncology
  • Respiratory
  • Others

By Country:

  • The United States
  • Canada
  • Rest of North America

Geographically, the U.S. generic drugs market had the highest share of the market in the world in 2020. The generic drugs market in the United States is anticipated to develop rapidly between 2021 and 2026. Generic medicines have seen a significant increase in manufacturing in the United States since they are less expensive than branded pharmaceuticals and do not need considerable research and testing as generic medicines. Thus, it plays a crucial role in the US healthcare sector.

In comparison to the previous year, generic prescriptions increased by 2.2%. Apotex is Canada's largest manufacturer; it is owned and managed by itself. There are around 15 generic medication providers, with 13 businesses having production facilities in the nation.


A few of the promising companies operating in the North America generic drugs market profiled in the report are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.


                1.1 Market Definition    

                1.2 Study Deliverables  

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions

2. Research Methodology     

                2.1 Introduction        

                2.2 Research Phases      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design  

                2.4 Study Timeline   

3. Overview 

                3.1 Executive Summary

                3.2 Key Inferences  

                3.3 Epidemology       

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)             

                4.1 Market Drivers   

                4.2 Market Restraints    

                4.3 Key Challenges  

                4.4 Current Opportunities in the Market       

5. Market Segmentation        

                5.1 Type       

                                5.1.1 Introduction           

                                5.1.2 Biosimilars               

                                5.1.3 simple generics     

                                5.1.4 Super generics      

                                5.1.5  Y-o-Y Growth Analysis, By Product              

                                5.1.6  Market Attractiveness Analysis, By Product            

                                5.1.7  Market Share Analysis, By Product              

                5.2 Therapeutic drugs   

                                5.2.1 Introduction           

                                5.2.2 Cardiovascular Products    

                                5.2.3 Anti-infective Drugs            

                                5.2.4 Anti Arthritis Drugs              

                                5.2.5 Central Nervous System Drugs       

                                5.2.6 Anti Cancer Drugs

                                5.2.7 Respiratory System Drugs

                                5.2.8 Others      

                                5.2.9 Y-o-Y Growth Analysis, By Therapeutic Drugs          

                                5.2.10 Market Attractiveness Analysis, By Therapeutic Drugs      

                                5.2.11 Market Share Analysis, By Therapeutic Drugs        

6. Geographical Analysis        

                6.1 Introduction        

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis By Geographical Area                              By Type                          By Therapeutic Drugs                                      

                                6.1.4  Market Attractiveness Analysis By Geographical Area                              By Type                          By Therapeutic Drugs                                      

                                6.1.5  Market Share Analysis By Geographical Area                              By type                          By Therapeutic Drugs                                      

                6.2 United States     

                6.3 Canada  

7.Strategic Analysis  

                7.1 PESTLE analysis  

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis       

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis   

                8.1 Ranbaxy Laboratories     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Actavis   

                8.3 Mylan, Inc. Industries, Ltd.  

                8.4 Dr. Reddy’s Laboratories      

                8.5 Par Pharmaceutical, Inc. 

                8.6 Sandoz International GmbH

                8.7 Celgene Corporation       

                8.8 Apotex, Inc.        

                8.9 Watson Pharmaceuticals, Ltd.     

                8.10 Teva Pharmaceutical and others.    

9.Competitive Landscape      

                9.1 Market share analysis     

                9.2 Merger and Acquisition Analysis

                9.3 Agreements, collaborations and Joint Ventures  

                9.4 New Product Launches  

10.Market Outlook and Investment Opportunities    


                a) List of Tables

                b) List of Figures       

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Generic Drugs Market, By Type, From 2021 to 2026 (USD Million)
  2. North America Biosimilars Market, By Region, From 2021 to 2026 (USD Million)
  3. North America Simple Generics Market, By Region, From 2021 to 2026 (USD Million)
  4. North America Super Generics Market, By Region, From 2021 to 2026 (USD Million)
  5. North America Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Million)
  6. North America Cardiovascular Drugs Market, By Region, From 2021 to 2026 (USD Million)
  7. North America Anti-Infective Drugs Market, By Region, From 2021 to 2026 (USD Million)
  8. North America Anti-Arthritic Drugs Market, By Region, From 2021 to 2026 (USD Million)
  9. North America Central Nervous system Drugs Market, By Region, From 2021 to 2026 (USD Million)
  10. North America Anti-Cancer Drugs Market, By Region, From 2021 to 2026 (USD Million)
  11. North America Respiratory Products Market, By Region, From 2021 to 2026 (USD Million)
  12. North America Others Market, By Region, From 2021 to 2026 (USD Million)
  13. United States Generic Drugs Market, By Type, From 2021 to 2026 (USD Million)
  14. United States Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Million)
  15. Canada Generic Drugs Market, By Type, From 2021 to 2026 (USD Million)
  16. Canada Generic Drugs Market, By Therapeutic Drugs, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports


$ 1234 3335

Click for Request Sample